GSK Investigational Site

Torrington, Connecticut 06790

0 studies enrolling now · 3 studies all time

What they study most

Irritable Colon, Lung Cancer, Non-Small Cell, Neoplasms, Breast

Studies at this site

• GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer — Stopped early
• Eight-Weeks Of Treatment With Talnetant In Subjects With Irritable Bowel Syndrome (IBS) — Completed
• Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer — Completed